Interstitial Granulomatous Drug Reaction to Ustekinumab

Interstitial granulomatous drug reaction (IGDR) is a distinct inflammatory process that often presents as annular, violaceous plaques distributed on the extremities, proximal trunk, and intertriginous areas. The list of drugs implicated for inciting IGDR is growing, but most prominently includes ACE...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, A., Westerdahl, J. S., Zussman, J., Mathis, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975670/
https://www.ncbi.nlm.nih.gov/pubmed/35371573
http://dx.doi.org/10.1155/2022/1461145
_version_ 1784680414819909632
author Walker, A.
Westerdahl, J. S.
Zussman, J.
Mathis, J.
author_facet Walker, A.
Westerdahl, J. S.
Zussman, J.
Mathis, J.
author_sort Walker, A.
collection PubMed
description Interstitial granulomatous drug reaction (IGDR) is a distinct inflammatory process that often presents as annular, violaceous plaques distributed on the extremities, proximal trunk, and intertriginous areas. The list of drugs implicated for inciting IGDR is growing, but most prominently includes ACE inhibitors, antihistamines, beta-blockers, antidepressants, and anticonvulsants. Ustekinumab is a human monoclonal antibody that targets inflammatory cytokines IL-12 and IL-23 and has been have shown to be effective in treating IGDR. However, we present a case that suggests ustekinumab can also act as an inciting agent for IGDR.
format Online
Article
Text
id pubmed-8975670
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89756702022-04-02 Interstitial Granulomatous Drug Reaction to Ustekinumab Walker, A. Westerdahl, J. S. Zussman, J. Mathis, J. Case Rep Dermatol Med Case Report Interstitial granulomatous drug reaction (IGDR) is a distinct inflammatory process that often presents as annular, violaceous plaques distributed on the extremities, proximal trunk, and intertriginous areas. The list of drugs implicated for inciting IGDR is growing, but most prominently includes ACE inhibitors, antihistamines, beta-blockers, antidepressants, and anticonvulsants. Ustekinumab is a human monoclonal antibody that targets inflammatory cytokines IL-12 and IL-23 and has been have shown to be effective in treating IGDR. However, we present a case that suggests ustekinumab can also act as an inciting agent for IGDR. Hindawi 2022-03-25 /pmc/articles/PMC8975670/ /pubmed/35371573 http://dx.doi.org/10.1155/2022/1461145 Text en Copyright © 2022 A. Walker et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Walker, A.
Westerdahl, J. S.
Zussman, J.
Mathis, J.
Interstitial Granulomatous Drug Reaction to Ustekinumab
title Interstitial Granulomatous Drug Reaction to Ustekinumab
title_full Interstitial Granulomatous Drug Reaction to Ustekinumab
title_fullStr Interstitial Granulomatous Drug Reaction to Ustekinumab
title_full_unstemmed Interstitial Granulomatous Drug Reaction to Ustekinumab
title_short Interstitial Granulomatous Drug Reaction to Ustekinumab
title_sort interstitial granulomatous drug reaction to ustekinumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975670/
https://www.ncbi.nlm.nih.gov/pubmed/35371573
http://dx.doi.org/10.1155/2022/1461145
work_keys_str_mv AT walkera interstitialgranulomatousdrugreactiontoustekinumab
AT westerdahljs interstitialgranulomatousdrugreactiontoustekinumab
AT zussmanj interstitialgranulomatousdrugreactiontoustekinumab
AT mathisj interstitialgranulomatousdrugreactiontoustekinumab

Ejemplares similares